List of Kombiglyze Xr drug patents

Kombiglyze Xr is owned by Astrazeneca Ab.

Kombiglyze Xr contains Metformin Hydrochloride; Saxagliptin Hydrochloride.

Kombiglyze Xr has a total of 3 drug patents out of which 0 drug patents have expired.

Kombiglyze Xr was authorised for market use on 05 November, 2010.

Kombiglyze Xr is available in tablet, extended release;oral dosage forms.

Kombiglyze Xr can be used as method for treating type ii diabetes mellitus by administering saxagliptin in combination with metformin; adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus when treatment with both saxagliptin and metformin is appropriate.

The generics of Kombiglyze Xr are possible to be released after 13 July, 2025.

KOMBIGLYZE XR's oppositions filed in EPO
KOMBIGLYZE XR Litigations
Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
USRE44186 ASTRAZENECA AB Cyclopropyl-fused pyrrolidine-based inhibitors of dipeptidyl peptidase IV and method
Jul, 2023

(4 months from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9339472 ASTRAZENECA AB Coated tablet formulation and method
Jul, 2025

(2 years from now)

US8628799 ASTRAZENECA AB Coated tablet formulation and method
Jul, 2025

(2 years from now)

Drugs and Companies using METFORMIN HYDROCHLORIDE; SAXAGLIPTIN HYDROCHLORIDE ingredient

Market Authorisation Date: 05 November, 2010

Treatment: Method for treating type ii diabetes mellitus by administering saxagliptin in combination with metformin; Adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellit...

Dosage: TABLET, EXTENDED RELEASE;ORAL

How can I launch a generic of KOMBIGLYZE XR before it's patent expiration?
More Information on Dosage

KOMBIGLYZE XR family patents

7

United States

3

Slovenia

3

Spain

3

European Union

2

Israel

2

Denmark

2

Hong Kong

2

Hungary

2

Argentina

2

Croatia

2

Portugal

2

Cyprus

2

Korea, Republic of

2

Poland

2

Taiwan, Province of China

2

RS

2

China

2

ME

1

South Africa

1

Mexico

1

Australia

1

Russia

1

Lithuania

1

Norway

1

Brazil

1

Malaysia

1

Peru

1

Georgia

1

Ukraine

1

Japan

1

Canada

1

New Zealand

900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight

Join them to stay ahead in capturing the next drug going generic

Other things you might be interested in